1. Home
  2. TVRD vs MYO Comparison

TVRD vs MYO Comparison

Compare TVRD & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$4.37

Market Cap

37.3M

Sector

Health Care

ML Signal

HOLD

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$0.89

Market Cap

36.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVRD
MYO
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.3M
36.9M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TVRD
MYO
Price
$4.37
$0.89
Analyst Decision
Buy
Strong Buy
Analyst Count
7
3
Target Price
$51.67
$7.67
AVG Volume (30 Days)
109.7K
572.3K
Earning Date
02-21-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,643,203.00
Revenue This Year
N/A
$24.07
Revenue Next Year
N/A
$17.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.00
52 Week Low
$3.74
$0.71
52 Week High
$43.65
$6.44

Technical Indicators

Market Signals
Indicator
TVRD
MYO
Relative Strength Index (RSI) 44.12 41.61
Support Level $4.39 $0.92
Resistance Level $4.89 $1.02
Average True Range (ATR) 0.31 0.07
MACD 0.05 -0.01
Stochastic Oscillator 43.63 17.58

Price Performance

Historical Comparison
TVRD
MYO

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Share on Social Networks: